Wegovy and Mounjaro treatments are recommended for adults with a body mass index (BMI) of 30 or higher, classified as obesity. They may also be suitable for individuals with a BMI between 27 kg/m² and 30, classified as overweight, if accompanied by weight-related health conditions such as prediabetes, high blood pressure, sleep apnea, high cholesterol, or heart disease.
Weight loss medications, including Wegovy and Mounjaro, should only be considered if attempts at weight loss through diet and exercise have been unsuccessful. Other GLP-1 medications in this category include Saxenda, Wegovy, Mounjaro, and Ozempic.
These GLP-1 drugs are appropriate for individuals with:
- A BMI over 30
- A BMI over 27 with additional risk factors, such as:
- Type 2 diabetes
- High cholesterol
- Obstructive sleep apnea
- High blood pressure
Eligibility thresholds for treatment may vary for certain ethnic groups.
Additionally, for individuals transferring from another provider with documented evidence of successful prior use of these medications, a lower BMI threshold may be considered. Such cases are assessed individually.